HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correction (v132,p565) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Robert James Cerfolio Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cerfolio, R. J. Articles by Ojha, B. Search for Related Content PubMed PubMed Citation Articles by Cerfolio, R. J. Articles by Ojha, B. Related Collections Lung - cancer Mediastinum Related Article

J Thorac Cardiovasc Surg 2006;131:1229-1235
© 2006 The American Association for Thoracic Surgery

General Thoracic Surgery

Restaging patients with N2 (stage IIIa) non–small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study

^a Division of Thoracic Surgery, University of Alabama at Birmingham, and the Division of Cardio-Thoracic Surgery, Department of Surgery, Birmingham Veterans Administration Hospital, Birmingham, Ala
^b Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Ala
^c Division of Nuclear Radiology, University of Alabama, Birmingham, Ala

Received for publication May 30, 2005; revisions received August 24, 2005; accepted for publication August 30, 2005.

^_* Address for reprints: Robert J. Cerfolio, MD, Associate Professor of Surgery, Chief of Thoracic Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, 1900 University Blvd, THT 712, Birmingham, AL 35294 (Email: Robert.cerfolio{at}ccc.uab.edu).

BACKGROUND: The accuracy of restaging in patients with stage IIIa non–small cell lung cancer after neoadjuvant chemoradiotherapy is unknown.

METHODS: A prospective trial of patients with biopsy-proven N2 disease who underwent initial clinical staging with mediastinoscopy, integrated positron emission tomography/computed tomography (PET/CT), and CT. Patients then were clinically restaged by the same imaging techniques 4 to 12 weeks after their induction chemoradiation therapy and then underwent definitive pathologic staging.

RESULTS: Ninety-three patients had their lymph nodes pathologically restaged. Repeat PET/CT after neoadjuvant therapy missed residual N2 disease in 13/65 (20%) patients and falsely suggested it in 7 of 28 (25%). It was more accurate than repeat CT for restaging at all pathologic stages (stage 0, 92% vs 39%, P = .03; and stage I 89% vs 36%, P = .04). When the maximum standardized uptake value of the primary tumor is decreased by 75% or more, it is highly likely (likelihood ratio, +LR, 6.1) the patient is a complete responder; when it decreased by 55% or more, it is highly likely (+LR, 9.1) the patient is a partial responder. When the maximum standardized uptake value of the N2 node initially involved with metastatic cancer is decreased by more than 50%, it is highly likely (+LR, 7.9) the node is now benign.

CONCLUSION: Repeat integrated PET/CT is superior to repeat CT for the restaging of patients with stage IIIa non–small cell lung cancer. The percent decrease in the maximum standardized uptake value of the primary and of the involved lymph node is predictive of pathology; however, nodal biopsies are required since a persistently high maximum standardized uptake value does not equate to residual cancer.

Related Article

Optimal management of patients with non–small cell lung cancer with ipsilateral mediastinal lymph node metastases

Richard J. Battafarano
J. Thorac. Cardiovasc. Surg. 2006 131: 1227-1228. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				J. J. Erasmus, E. Rohren, and S. G. Swisher Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging Proceedings of the ATS, April 15, 2009; 6(2): 171 - 179. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio Counterpoint: Despite staging inaccuracies, patients with non-small cell lung cancer are best served by having integrated positron emission tomography/computed tomography before therapy. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 20 - 22. [Full Text] [PDF]

				A. P. Brown, D. S. Wendler, K. A. Camphausen, F. G. Miller, and D. Citrin Performing Nondiagnostic Research Biopsies in Irradiated Tissue: A Review of Scientific, Clinical, and Ethical Considerations J. Clin. Oncol., August 20, 2008; 26(24): 3987 - 3994. [Abstract] [Full Text] [PDF]

				P. E. Van Schil and M. De Waele A second mediastinoscopy: how to decide and how to do it? Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 703 - 706. [Abstract] [Full Text] [PDF]

				A. Marra, L. Hillejan, S. Fechner, and G. Stamatis Remediastinoscopy in restaging of lung cancer after induction therapy. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 843 - 849. [Abstract] [Full Text] [PDF]

				C. Dooms, E. Verbeken, S. Stroobants, K. Nackaerts, P. De Leyn, and J. Vansteenkiste Prognostic Stratification of Stage IIIA-N2 Non-Small-Cell Lung Cancer After Induction Chemotherapy: A Model Based on the Combination of Morphometric-Pathologic Response in Mediastinal Nodes and Primary Tumor Response on Serial 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography J. Clin. Oncol., March 1, 2008; 26(7): 1128 - 1134. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio and A. S. Bryant When is it Best to Repeat a 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant Chemoradiotherapy? Ann. Thorac. Surg., October 1, 2007; 84(4): 1092 - 1097. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, and M. A. Eloubeidi Accessing the Aortopulmonary Window (#5) and the Paraaortic (#6) Lymph Nodes in Patients With Non-Small Cell Lung Cancer Ann. Thorac. Surg., September 1, 2007; 84(3): 940 - 945. [Abstract] [Full Text] [PDF]

				L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 243S - 265S. [Abstract] [Full Text] [PDF]

				P. De Leyn, D. Lardinois, P. E. Van Schil, R. Rami-Porta, B. Passlick, M. Zielinski, D. A. Waller, T. Lerut, and W. Weder ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 1 - 8. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio and A. S. Bryant Surgical Techniques and Results for Partial or Circumferential Sleeve Resection of the Pulmonary Artery for Patients with Non-Small Cell Lung Cancer Ann. Thorac. Surg., June 1, 2007; 83(6): 1971 - 1977. [Abstract] [Full Text] [PDF]

				M. Okada, S. Tauchi, K. Iwanaga, T. Mimura, Y. Kitamura, H. Watanabe, S. Adachi, T. Sakuma, and C. Ohbayashi Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1448 - 1454. [Abstract] [Full Text] [PDF]

				P. Granone, P. Van Schil, and A. Cesario Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A closer look at redo mediastinoscopy J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 275 - 276. [Full Text] [PDF]

				J. Czernin, M. Allen-Auerbach, and H. R. Schelbert Improvements in Cancer Staging with PET/CT: Literature-Based Evidence as of September 2006 J. Nucl. Med., January 1, 2007; 48(1_suppl): 78S - 88S. [Abstract] [Full Text] [PDF]

				R. J. Battafarano Optimal management of patients with non-small cell lung cancer with ipsilateral mediastinal lymph node metastases J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1227 - 1228. [Full Text] [PDF]